Motor activity is modulated via different neuronal circuits in rats with chronic liver failure than in normal rats.
The mechanisms by which liver failure alters motor function remain unclear. It has been suggested that liver disease alters the neuronal circuit between basal ganglia and cortex that modulates motor function. Activation of group I metabotropic glutamate receptors in the nucleus accumbens (NAcc) by injecting (S)-3,5-dihydroxyphenylglycine (DHPG) activates this circuit and induces locomotion We analysed by in vivo brain microdialysis the function of the circuits that modulate motor function in rats with liver failure due to portacaval shunt (PCS). We inserted cannulae in the NAcc and microdialysis probes in the NAcc, ventral pallidum (VP), substantia nigra pars reticulata (SNr), medio-dorsal thalamus (MDT), ventro-medial thalamus (VMT) or prefrontal cortex (PFCx). We injected DHPG in the NAcc and analysed extracellular neurotransmitters concentration in these areas. The results indicate that in control rats DHPG induces locomotion by activating the 'normal' neuronal circuit: NAcc --> VP --> MDT --> PFCx. In PCS rats this circuit is not activated. In PCS rats, DHPG injection activates an 'alternative' circuit: NAcc --> SNr --> VMT --> PFCx. This circuit is not activated in control rats. DHPG injection increases dopamine in the NAcc of control but not of PCS rats, and glutamate in PCS but not in control rats. DHPG-induced increase in dopamine would activate the 'normal' neuronal circuit, while an increase in glutamate would activate the 'alternative' circuit. The identification of the mechanisms responsible for altered motor function and coordination in liver disease would allow designing treatments to improve motor function in patients with hepatic encephalopathy.
Cauli
Omar
O
Laboratory of Neurobiology, Centro de Investigacion Príncipe Felipe, Valencia, Spain.
Mlili
Nisrin
N
Llansola
Marta
M
Felipo
Vicente
V
D000818:Animals; D001522:Behavior, Animal / Q000502:physiology; D001921:Brain / Q000033:anatomy & histology* / Q000378:metabolism; D002908:Chronic Disease; D004298:Dopamine / Q000378:metabolism; D018690:Excitatory Amino Acid Agonists / Q000008:administration & dosage / Q000378:metabolism; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage / Q000378:metabolism; D018698:Glutamic Acid / Q000378:metabolism; D005998:Glycine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000378:metabolism; D006801:Humans; D017093:Liver Failure / Q000503:physiopathology*; D008297:Male; D017551:Microdialysis; D009043:Motor Activity / Q000502:physiology*; D009434:Neural Pathways / Q000033:anatomy & histology / Q000502:physiology*; D009474:Neurons / Q000166:cytology / Q000378:metabolism*; D011167:Portacaval Shunt, Surgical; D051381:Rats; D017208:Rats, Wistar; D012118:Resorcinols / Q000008:administration & dosage / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D018690:Excitatory Amino Acid Agonists; D018691:Excitatory Amino Acid Antagonists; D012118:Resorcinols; D018698:Glutamic Acid; D005680:gamma-Aminobutyric Acid; C079215:3,5-dihydroxyphenylglycine; D005998:Glycine; D004298:Dopamine